» Articles » PMID: 27499923

High-throughput Automated Scoring of Ki67 in Breast Cancer Tissue Microarrays from the Breast Cancer Association Consortium

Abstract

Automated methods are needed to facilitate high-throughput and reproducible scoring of Ki67 and other markers in breast cancer tissue microarrays (TMAs) in large-scale studies. To address this need, we developed an automated protocol for Ki67 scoring and evaluated its performance in studies from the Breast Cancer Association Consortium. We utilized 166 TMAs containing 16,953 tumour cores representing 9,059 breast cancer cases, from 13 studies, with information on other clinical and pathological characteristics. TMAs were stained for Ki67 using standard immunohistochemical procedures, and scanned and digitized using the Ariol system. An automated algorithm was developed for the scoring of Ki67, and scores were compared to computer assisted visual (CAV) scores in a subset of 15 TMAs in a training set. We also assessed the correlation between automated Ki67 scores and other clinical and pathological characteristics. Overall, we observed good discriminatory accuracy (AUC = 85%) and good agreement (kappa = 0.64) between the automated and CAV scoring methods in the training set. The performance of the automated method varied by TMA (kappa range= 0.37-0.87) and study (kappa range = 0.39-0.69). The automated method performed better in satisfactory cores (kappa = 0.68) than suboptimal (kappa = 0.51) cores (p-value for comparison = 0.005); and among cores with higher total nuclei counted by the machine (4,000-4,500 cells: kappa = 0.78) than those with lower counts (50-500 cells: kappa = 0.41; p-value = 0.010). Among the 9,059 cases in this study, the correlations between automated Ki67 and clinical and pathological characteristics were found to be in the expected directions. Our findings indicate that automated scoring of Ki67 can be an efficient method to obtain good quality data across large numbers of TMAs from multicentre studies. However, robust algorithm development and rigorous pre- and post-analytical quality control procedures are necessary in order to ensure satisfactory performance.

Citing Articles

TMA-Mate: An open-source modular toolkit for constructing tissue microarrays of arbitrary layouts.

Pazaitis N, Kaiser A HardwareX. 2023; 14:e00419.

PMID: 37128356 PMC: 10148229. DOI: 10.1016/j.ohx.2023.e00419.


The Approach of Artificial Intelligence in Neuroendocrine Carcinomas of the Breast: A Next Step towards Precision Pathology?-A Case Report and Review of the Literature.

Chiorean D, Mitranovici M, Muresan M, Buicu C, Moraru R, Moraru L Medicina (Kaunas). 2023; 59(4).

PMID: 37109630 PMC: 10141693. DOI: 10.3390/medicina59040672.


Reliability of a computational platform as a surrogate for manually interpreted immunohistochemical markers in breast tumor tissue microarrays.

Roberts M, Baker G, Heng Y, Pyle M, Astone K, Rosner B Cancer Epidemiol. 2021; 74:101999.

PMID: 34352659 PMC: 8887925. DOI: 10.1016/j.canep.2021.101999.


Cutoff of 25% for Ki67 expression is a good classification tool for prognosis in colorectal cancer in the AJCC‑8 stratification.

Tong G, Zhang G, Liu J, Zheng Z, Chen Y, Niu P Oncol Rep. 2020; 43(4):1187-1198.

PMID: 32323802 PMC: 7058009. DOI: 10.3892/or.2020.7511.


Combined quantitative measures of ER, PR, HER2, and KI67 provide more prognostic information than categorical combinations in luminal breast cancer.

Abubakar M, Figueroa J, Ali H, Blows F, Lissowska J, Caldas C Mod Pathol. 2019; 32(9):1244-1256.

PMID: 30976105 PMC: 6731159. DOI: 10.1038/s41379-019-0270-4.


References
1.
Turbin D, Leung S, Cheang M, Kennecke H, Montgomery K, McKinney S . Automated quantitative analysis of estrogen receptor expression in breast carcinoma does not differ from expert pathologist scoring: a tissue microarray study of 3,484 cases. Breast Cancer Res Treat. 2007; 110(3):417-26. DOI: 10.1007/s10549-007-9736-z. View

2.
Candido Dos Reis F, Lynn S, Ali H, Eccles D, Hanby A, Provenzano E . Crowdsourcing the General Public for Large Scale Molecular Pathology Studies in Cancer. EBioMedicine. 2015; 2(7):681-9. PMC: 4534635. DOI: 10.1016/j.ebiom.2015.05.009. View

3.
Goldhirsch A, Winer E, Coates A, Gelber R, Piccart-Gebhart M, Thurlimann B . Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013. Ann Oncol. 2013; 24(9):2206-23. PMC: 3755334. DOI: 10.1093/annonc/mdt303. View

4.
Perou C, Sorlie T, Eisen M, van de Rijn M, Jeffrey S, Rees C . Molecular portraits of human breast tumours. Nature. 2000; 406(6797):747-52. DOI: 10.1038/35021093. View

5.
Rudolph P, Olsson H, Bonatz G, Ratjen V, Bolte H, Baldetorp B . Correlation between p53, c-erbB-2, and topoisomerase II alpha expression, DNA ploidy, hormonal receptor status and proliferation in 356 node-negative breast carcinomas: prognostic implications. J Pathol. 1999; 187(2):207-16. DOI: 10.1002/(SICI)1096-9896(199901)187:2<207::AID-PATH223>3.0.CO;2-U. View